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There is an urgent need to identify new treatments for
fungal infections. By combining sub-lethal concen-
trations of the known antifungals fluconazole, caspo-
fungin, amphotericin B, terbinafine, benomyl, and
cyprodinil with 3,600 compounds in diverse fungal
species, we generated a deep reservoir of chemi-
cal-chemical interactions termed the Antifungal
CombinationsMatrix (ACM). Follow-up susceptibility
testing against a fluconazole-resistant isolate of
C. albicans unveiled ACM combinations capable
of potentiating fluconazole in this clinical strain. We
used chemical genetics to elucidate the mode of
action of the antimycobacterial drug clofazimine, a
compound with unreported antifungal activity that
synergized with several antifungals. Clofazimine in-
duces a cell membrane stress for which the Pkc1
signaling pathway is required for tolerance. Addi-
tional tests against additional fungal pathogens,
including Aspergillus fumigatus, highlighted that clo-
fazimine exhibits efficacy as a combination agent
against multiple fungi. Thus, the ACM is a rich reser-
voir of chemical combinations with therapeutic po-
tential against diverse fungal pathogens.INTRODUCTION
Fungal pathogens have emerged as a leading cause of human
mortality. Current estimates suggest death due to invasive fungal
infections is on par with more well-known infectious diseases
such as tuberculosis (Brown et al., 2012; Denning and Bromley,
2015), with costs to the health care system of$2.6 billion annu-Cell Repally in the United States alone (Wilson et al., 2002). These stag-
gering clinical and economic impacts are in large part due to
the limited number of validated cellular targets available in fungi
to exploit for drug discovery, and the ability of fungal pathogens
to thwart therapeutic regimens by evolving resistance to current
treatments. Candida albicans, Cryptococcus neoformans, and
Aspergillus fumigatus represent the most prevalent fungal path-
ogens of humans (Brown et al., 2012). Each of these species is
responsible for hundreds of thousands of infections annually
with unacceptably high mortality rates due to poor diagnostics
and limited treatment options (Brown et al., 2012). Furthermore,
the rapid emergence of drug resistance in Candida species
poses a serious threat to human health as identified by the Cen-
ters for Disease Control and Prevention (2013). The challenge
that remains in the medical mycology community is the identifi-
cation of therapies with efficacy against fungal pathogens while
maintaining minimal human toxicity.
A limited number of antifungal drugs exhibit selective toxicity
to fungi because of the evolutionary conservation of eukaryotic
gene function from fungi to humans. The polyenes, which cause
severe nephrotoxicity, form large extramembranous aggregates
that extract the essential membrane-lipid ergosterol from the
plasma membrane (Anderson et al., 2014). The azoles inhibit
ergosterol biosynthesis and impede cellular growth, but because
these compounds are merely fungistatic resistance is readily ac-
quired. The only new class of antifungal to reach the clinic in de-
cades is the echinocandins, which inhibit synthesis of b-(1,3)
glucan, a key component of the fungal cell wall (Ostrosky-Zeich-
ner et al., 2010). This paucity of fungal-specific targets is prob-
lematic given the prevalence of cross-resistance to all drugs
with a common target, and indeed resistance to all widely de-
ployed antifungals has been documented in both the laboratory
and the clinic (Shapiro et al., 2011).
Despite efforts over the past several decades to discover novel
treatments for fungal infections, there remains a paucity of new
drug leads and new drug targets. Recent efforts to understandorts 13, 1481–1492, November 17, 2015 ª2015 The Authors 1481
the complex networks that underpin the biology of fungi in model
species suggest new therapeutic strategies. Large-scale genetic
and proteomic studies in the budding yeast Saccharomyces
cerevisiae have revealed that cellular behavior is controlled by
a highly interconnected and functionally redundant network
of gene and protein interactions (Costanzo et al., 2010; Sharom
et al., 2004). While only 1,000 of the 6,000 genes in
S. cerevisiae are essential for growth, systematic efforts to simul-
taneously disrupt any two non-essential genes in the same
cell has revealed over 170,000 synthetic lethal combinations
(Costanzo et al., 2010). This redundancy, referred to as genetic
buffering, in part explains the difficulty of identifying single
compounds that result in cellular toxicity. The vast network of
synthetic lethal genetic interactions represents an untapped
target space for drug discovery, as, in principle, combinations
of compounds that perturb fungal genetic networks at two
or more nodes may result in selective toxicity. Furthermore,
combinatorial inhibition can confer enhanced efficacy and spec-
ificity compared to individual drug treatments and can slow the
evolution of resistance (Zimmermann et al., 2007). Ad hoc drug
combinations discovered by trial and error have been widely
used against many diseases. For example, the current gold stan-
dard antifungal regimen for cryptococcal meningitis is a combi-
nation of amphotericin B and 5-flucytosine (Day et al., 2013).
The systematic discovery of active drug combinations to treat
fungal infections, predicated on the concept of extensive genetic
network redundancy, is a potentially rich sourceof newantifungal
agents.
The re-purposing of previously approved drugs for new indi-
cations has emerged as one means to expedite drug develop-
ment because the known toxicology and pharmacology lowers
regulatory barriers and cost. The combination of established an-
tifungals with re-purposed drugs from other indications holds
considerable promise. In an early example, calcineurin or target
of rapamycin (TOR) inhibitors improved the efficacy of flucona-
zole against a variety of pathogenic fungi (Blankenship et al.,
2003). More recently, the Hsp90 inhibitor 17-AAG was found
to synergize with fluconazole against C. albicans in a Galleria
mellonella model of systemic candidiasis, and in a rat catheter
model of biofilm infection (Cowen et al., 2009; Robbins et al.,
2011). A large-scale systematic analysis of chemical-chemical
interactions identified 148 bioactive molecules that potentiate
the activity of fluconazole toward diverse fungal species,
including clinical pathogens (Spitzer et al., 2011). Another screen
of off-patent drugs revealed 15 compounds with activity against
C. neoformans (Butts et al., 2013). High-throughput screens for
synergistic enhancers of known antifungal agents thus have
the potential to yield effective combination therapeutics against
clinically relevant pathogens.
In this study, we screened sub-lethal concentrations of six
known antifungals in combination with3,600 different bioactive
compounds to uncover synergistic drug combinations. Parallel
screens were performed in the model yeasts S. cerevisiae
and Schizosaccharomyces pombe, as well as in the fungal
pathogens C. albicans and C. neoformans to generate the
most comprehensive analysis of drug combinations in fungi to
date. This dataset of drug interactions, which we have termed
the Antifungal Combination Matrix (ACM), contains hundreds1482 Cell Reports 13, 1481–1492, November 17, 2015 ª2015 The Auof chemical combinations that abrogate fungal growth, often in
an antifungal- and species-specific manner. We show that a
number of antifungal combinations are active toward an isolate
of C. albicans that had acquired fluconazole resistance in the
clinic. Chemical-genetic profiling of clofazimine, an antimyco-
bacterial agent for which antifungal activity has not been
described, suggested that it induces a Pkc1-dependent cell
membrane stress response. We further show that clofazimine
is a general potentiator of antifungal activity in fungal species
separated by 1 billion years of evolution. Thus, the ACM repre-
sents a unique resource of chemical probes for the study of
fungal biology, and an entry point for discovery of combination
therapeutics against diverse fungal pathogens.
RESULTS
The Antifungal Combination Matrix
To identify molecules that potentiate known antifungal agents,
we selected six entry-point drugs. We chose four clinically
relevant drugs with well-characterized targets: amphotericin
B (ergosterol, cell membrane), fluconazole (Erg11; ergosterol
biosynthesis), terbinafine (Erg1; ergosterol biosynthesis), and
caspofungin (b-glucan synthase, cell wall synthesis). We also
selected two agricultural fungicides: benomyl, a microtubule
inhibitor, and cyprodinil, a compound whose mode of action re-
mains enigmatic. High-throughput combination screens were
performed against four different fungal species: S. cerevisiae,
S. pombe, C. albicans, and C. neoformans. These evolutionarily
divergent genera were chosen in order to identify combination
agents in model yeast species where mode of action can be
readily probed using advanced functional genomic reagents,
and in clinically relevant fungal pathogens. Each species was
screened using compounds from the McMaster Bioactives
collection, a library of 3,600 unique small molecules derived
from commercial sources. All of the screens were performed
with 12.5 mM of compound in the absence and presence of
1/4 minimum inhibitory concentration (MIC) of the antifungal
drug (Table S1). This concentration regimen enabled identifica-
tion of antifungal potentiators that had minimal growth effects
on their own. Residual activity was calculated for each com-
pound, and data were normalized for plate- and row/column-
specific effects as described previously (Table S2) (Spitzer
et al., 2011). Compounds that were greater than three median
absolute deviations (MADs) below the diagonal had less than
50% reduction of growth on their own and resulted in greater
than 80% growth inhibition in the presence of antifungal were
chosen for further analysis (Figure S1). This dataset called the
antifungal combination matrix (ACM) contained over 228,000
data points for 86,000 unique pairwise chemical-chemical in-
teractions and identified 1,550 drug combinations that showed
efficacy against at least one fungal species (Figure 1; Table
S3). The ACM represents the largest high-throughput screening
effort for combination agents against model yeasts and patho-
genic fungi.
To evaluate how the 1,550 active compounds identified in
the ACM are related to one another, we displayed the hits as
a comprehensive network of chemical-chemical interactions
that connect each antifungal entry-point drug to the chemicalsthors
Figure 1. The ACM Chemical-Chemical Interaction Network
The central chemical-chemical interaction network comprises a total of 1,550
chemical interactions. Compounds that potentiated an antifungal are depicted
as circles and are connected by edges to the antifungal in which synergy is
observed. Edges are colored to represent interactions identified against
different fungal species with blue representing C. albicans, green representing
S. cerevisiae, orange representing C. neoformans, and red representing
S. pombe. Antifungals are shown as black diamonds. (Amphotericin B [A],
benomyl [B], caspofungin [CF], cyprodinil [CY], fluconazole [F], or terbinafine
[T]). Chemical-chemical networks for each individual species are plotted in
corners and are colored as described above. See also Figures S1 and S2 and
Tables S1, S2, and S3.that were screened as a function of the species in which the
interaction was identified (Figure 1). This unveiled an intricate
pattern of chemical-chemical combinations capable of abro-
gating fungal growth. Different screens had dramatically different
numbers of compounds that increased the efficacy of each
antifungal agent, with hit rates as high as 7.4% for the amphoter-
icin B screen performed in C. neoformans and as low as 0.18%
for the benomyl screen performed in C. neoformans (Figure 1).
These hit rates were within the range reported from other drug
combination screens (Borisy et al., 2003; Spitzer et al., 2011).
More potentiators were identified with the antifungals caspo-
fungin and amphotericin B, which disrupt cell wall or membrane
(Figure 1). Benomyl, cyprodinil, fluconazole, and terbinafine
had markedly fewer hits that were more drug specific (Figures
1 and S2), demonstrating different antifungal classes elicitCell Repdramatically different rates of potentiation with other small
molecules.
The vast majority of the hits in the ACM were species and/or
antifungal specific, with only 22 compounds identified in more
than five screens. We visualized all compounds in a heatmap
to reveal the specific conditions linked by these ‘‘high-connectiv-
ity’’ compounds (Figure 2). Small molecules that were identified
most frequently as potentiators included tomatidine and chlor-
hexidine, identified in 13 and 12 screens, respectively. Notably,
both of these molecules are reported membrane perturbing
agents (Gilbert and Moore, 2005; Simons et al., 2006). Separate
chemical-species interaction networks for each antifungal drug
revealed species-specific effects elicited by a majority of the
combination treatments explored (Figure S2). For example, mol-
ecules that increased the efficacy of fluconazole, terbinafine,
benomyl, and cyprodinil were largely antifungal specific with
little overlap across the different fungal species (Figure S2).
In contrast, when examining potentiators of amphotericin B,
C. neoformans and C. albicans shared the largest number of
hits, whereasC. albicans and S. cerevisiae shared a high number
of caspofungin potentiators (Figure S2). In addition, C. albicans
and S. cerevisiae both had a high number of compounds that
increased the efficacy of both amphotericin B and caspofungin
(Figure 1). Overall, the ACM represents an extensive resource
of bioactive chemical space for antifungal drug discovery.
Hit Validation and Characterization
To explore a subset of the 1,550 hits from the ACM, we chose
eight compounds for additional drug susceptibility analysis.
These eight compounds were chosen based on diversity of
chemical class (Figure 3A), therapeutic use when known, and
the screens in which they were identified (Table S4). We tested
these eight compounds using standard concentration matrix
(checkerboard) assays in combination with the clinically relevant
antifungals caspofungin or fluconazole (Figure S3). Data were
quantified by calculation of the fractional inhibitory concentration
index (FICI), an accepted method for evaluating chemical inter-
actions in infectious disease (Figure 3B) (Odds, 2003). Drug inter-
actions are synergistic if the calculated FICI is below of 0.5,
additive if the FICI is 0.5–0.99 and an FICI between 1.0 and 4.0
indicates no chemical-chemical interaction (Odds, 2003). Amio-
darone hydrochloride, asiatic acid, clofazimine, and cyclosporin
A were synergistic with caspofungin against C. albicans and
S. cerevisiae (Figure 3B; Table S5). Cyclosporin A was also syn-
ergistic with caspofungin against S. pombe, and clofazimine was
synergistic with caspofungin against C. neoformans (Figure 3B;
Table S5). Checkerboard assays performed with fluconazole
revealed tomatidine as a potent synergizer of fluconazole against
C. albicans, S. cerevisiae, and C. neoformans (Figure 3B; Table
S5). Similarly, clofazimine was synergistic with fluconazole
against S. cerevisiae and C. neoformans. All remaining drug in-
teractions were either additive of showed no interaction (Table
S5). In total, 72 checkerboard assays were conducted with
drug combinations from the primary screen. All hits from the
screens were confirmed except for thapsigargin with flucon-
azole against S. cerevisiae (Figures S3 and S5; Table S4). Over-
all, these detailed analyses verified interactions identified in
the ACM.orts 13, 1481–1492, November 17, 2015 ª2015 The Authors 1483
(legend on next page)
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Figure 3. ACMHit Validation and Character-
ization
(A) Structures of compounds identified as poten-
tiators in the ACM. The numbers shown in brackets
indicate the number of screens in which they were
identified. See also Table S4.
(B) Heatmap of drug interactions with caspofungin
or fluconazole in each species as measured by
fractional inhibition concentration index (FICI).
Light blue indicates synergistic drug interactions
(FICI <0.5); darker shades of blue represent
additivity (FICI 0.5–0.99); black represents no
interaction (FICI 1.0–4.0). Compounds tested in
combination with fluconazole were examined for
cidality. Red triangles indicate a fungicidal drug
combination, orange triangles indicate fungistatic
drug combinations, and white triangles indicate
conditions where no inhibition of growth was
observed mitigating cidality testing.
See also Figure S3 and Tables S4 and S5.A limitation of the azoles is that resistance readily evolves due
to the fungistatic nature of the drug (Shapiro et al., 2011). To
determine whether any compounds rendered fluconazole fungi-
cidal, we used tandem assays with an antifungal susceptibility
test followed by spotting onto rich medium without inhibitors.
We tested cidality for compounds that reduced growth in the
presence of fluconazole more so than growth in either drug
individually (Figure S3). An overwhelming majority of the chemi-
cal-chemical interactions evaluated transformed fluconazole to
a fungicidal drug (Figure 3B). These results suggest that the flu-Figure 2. High-Connectivity Compounds from the ACM
Those compounds that were identified in four or more screens were visualized on a heatmap. Black rectangles
the antifungal. Background color represents the number of screens in which a molecule was identified with d
pink representing four screens. The names of compounds that potentiated antifungals are listed on the rig
bottom. The heatmap is organized by species and similarity of screening hits. See also Figures S1 and S2 a
Cell Reports 13, 1481–1492, Noconazole enhancers may help suppress
the emergence of antifungal resistance.
Drug Combinations with Efficacy
against aC. albicansClinical Isolate
In clinical settings, many thousands of
antifungal-resistant infections are diag-
nosed every year, particularly flucona-
zole-resistant C. albicans (Centers for
Disease Control and Prevention, 2013).
Therefore, we evaluated the activity of flu-
conazole enhancers originally identified in
the ACM against a bona fide fluconazole-
resistant clinical isolate ofC.albicans.This
strain had a fluconazole MIC of 128 mg/ml,
250-fold higher than the laboratory
strain likely due to mutations identified in
the azole target ERG11 (Erg11R264K), as
well as in TAC1 (Tac1T225A), a transcrip-
tional activator of ABC transporters. Of
the 18 molecules tested, three increased
the susceptibility of the resistant clinicalisolate to fluconazole: chlorhexidine, tomatidine, and hypocrellin
A (Figure 4A). In order to assess the robustness of these drug in-
teractions, checkerboard assays were conducted, and the FICI
was used to evaluate synergy. All three molecules were highly
synergistic with fluconazole with FICI values below 0.5 (Fig-
ure 4B), unveiling drug combinations with potent activity against
a clinically relevant strain of C. albicans. Thus, a fraction of anti-
fungal combinations with activity against a wild-type strain of
C.albicansare able to inhibit thegrowthof afluconazole-resistant
clinical isolate.represent conditions wheremolecules potentiated
ark blue representing 12 or more screens and light
ht and screening conditions are highlighted at the
nd Tables S2 and S3.
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Figure 4. Drug Combinations with Efficacy
against a Clinically Resistant Isolate of
C. albicans
(A) The 18 compounds identified as potentiators of
fluconazole (FL) against C. albicans in the ACM
were tested against a fluconazole-resistant clinical
isolate.C. albicanswas grown in the absence (–) or
presence of 1/4 MIC (32 mg/ml) of FL in combina-
tion with the ACM hits (12.5 mM). Growth was
measured by OD600, and data were quantitatively
displayed with color using Treeview (see color bar).
(B) Checkerboard assays highlight drug in-
teractions between fluconazole with chlorhexidine,
hypocrellin A, or tomatidine. Growth was moni-
tored and analyzed as described in (A). White
numbers indicate calculated FICI values.Mechanism of Action of Clofazimine
Clofazimine is currently used as an antimycobacterial agent
but in our study showed broad-spectrum activity in combina-
tion with fluconazole and caspofungin. As clofazimine has not
been described as an antifungal, we interrogated the mecha-
nism of action using established genomic profilingmethods (Gia-
ever et al., 2004; Pierce et al., 2006). We profiled compound
action in haploinsufficiency profiling (HIP) screens, in which the
1,000 diploid deletion strains heterozygous for essential genes
were tested for drug sensitivity to identify candidate compound
targets. Genes that encode the target of a compound are ex-
pected to be hypersensitive to that compound, as indicated by
decreased fitness as measured by competitive growth (Giaever
et al., 2004; Pierce et al., 2006). We validated our implementation
of this methodology by re-identifying ERG11 as the established
target for fluconazole (Figure S4). The HIP profile generated for
clofazimine was distinct from that observed with fluconazole
in that a single gene was not markedly more sensitive to clofazi-
mine relative to other genes in the pool. Among the heterozygous
mutants most sensitive to clofazimine was NEO1, which en-
codes an essential aminophospholipid translocase required for
membrane trafficking and vacuolar biogenesis (Table S6).
NEO1 haploinsufficiency is induced by cationic amphiphilic
drugs (CADs) (Lee et al., 2014), a structural feature shared by
clofazimine.
We profiled clofazimine action in homozygous deletion
profiling (HOP) screens, in which the 5,000 deletion strains
for non-essential genes were tested for drug sensitivity to iden-
tify chemical-genetic interactions indirectly associated with the
compound target (Giaever et al., 2004; Pierce et al., 2006).
Several gene deletion strains were sensitive to clofazimine
including genes important for phospholipid transport, membrane
organization, vesicle-mediated transport, and localization (Fig-1486 Cell Reports 13, 1481–1492, November 17, 2015 ª2015 The Authorsure 5), processes associated with mem-
brane integrity and function (Lee et al.,
2014). Moreover, the chemical-genetic
profile observed with clofazimine is mark-
edly similar to the structurally related
membrane perturbing agent chlorproma-
zine (De Filippi et al., 2007). In addition,
deletion of the copper-related genesSOD1, CCS1, and CTR1 rendered cells sensitive to clofazimine
(Figure 5), a feature shared by compounds that elicit high
degrees of oxidative stress such as menadione (Lee et al.,
2014). Clofazimine sensitivity of the top haploid deletion strains
identified in our HOP analysis was confirmed using growth curve
analysis (Figure S4). Based on our chemogenomic profile, we
postulate that clofazimine may be exerting its effects by disrupt-
ing cellular membranes and/or through the generation of reactive
oxygen species.
Clofazimine Induces a Cell Membrane Stress Response
and Activates Pkc1
Our chemical-genetic profile implicated a dual mechanism of
action for clofazimine. First, we tested our hypothesis that clofa-
zimine elicits a cell membrane stress response. Chlorpromazine
and clofazimine are both CADs consisting of a hydrophobic tricy-
clic ring and a hydrophilic side chain (Figure 6A). The hydropho-
bic moiety of chlorpromazine allows it to intercalate into the
hydrocarbon phase of the membrane bilayer (De Filippi et al.,
2007). At physiological pH, the tertiary dimethylpropylamine is
protonated and engages in electrostatic interactions with cyto-
solic anionic lipids (Levin, 2005). Altering in vitro conditions by
decreasing the pH of culture medium renders chlorpromazine
in its protonated state prior to diffusion across the S. cerevisiae
membrane, blocking cellular entry and impeding its toxic effects
(De Filippi et al., 2007). We tested whether similar effects were
observed with clofazimine by spotting wild-type S. cerevisiae
and a rim101 mutant, which is hypersensitive to clofazimine,
onto agar buffered at pH 5.5 or pH 8. At pH 5.5, cells were resis-
tant to the effects of clofazimine (Figure 6B), presumably due
to electrostatic interactions with the cellular membrane that
blocked compound entry. At a more basic pH, clofazimine
entered the cell and inhibited growth, particularly in the rim101
Figure 5. Genome-wide Chemical-Genetic
Interactions for Clofazimine
(A) Sensitivity of heterozygous essential deletion
strains (gray circles) and homozygous deletion
strains (blue circles) to clofazimine as assessed by
HIP and HOP. Data represent the average Z score
for two biological replicates. Those haploid dele-
tion strains that have a Z score more significant
than three SDs below the mean are highlighted in
red. No heterozygous deletion strains were iden-
tified with a Z score less than three SDs below the
mean. See also Table S6.
(B) Gene Ontology (GO) Biological Process terms
were generated for those deletion mutants that
were at least two SDsmore sensitive to clofazimine
than the mean population. p values were calcu-
lated using PANTHER Overrepresentation Test via
GO Ontology Database.
See also Figure S4.mutant (Figure 6B). This suggests clofazimine interacts with the
cellular membrane in a similar manner to chlorpromazine.
Drug-induced phospholipidosis (DIPL) is a phospholipid stor-
age disorder associated with CADs. In yeast, DIPL arises from
the selective buildup of CADs in the acidic vacuole; however,
loss of acidification reduces intracellular drug accumulation
and mitigates toxicity (Anderson and Borlak, 2006). Inhibition
of yeast vacuolar adenosine triphosphatase by bafilomycin A
alleviated the fitness defect induced by clofazimine (p < 0.01,
ANOVA, Bonferroni’s multiple comparison test, Figure 6C), in a
similar manner to other CADs (Lee et al., 2014), supporting our
hypothesis that clofazimine exerts its toxic effects through
non-specific membrane perturbations. As high temperature
increases turgor pressure and membrane stress on the cell
(Levin, 2005), we predicted enhanced synergy between clofazi-
mine and caspofungin at elevated temperature. Growth of both
S. cerevisiae and C. albicans at 39C exacerbated the synergy
observed between caspofungin and clofazimine (Figure 6D).
Perturbation of the cell membrane and/or cell wall can often
be rescued by osmotic stabilization. In both S. cerevisiae and
C. albicans, the addition of the osmotic stabilizer sorbitol abro-
gated synergy observed between caspofungin and clofazimine
(Figure S5A), suggesting osmotic support reduces the effects
of membrane stress caused by clofazimine. Checkerboard as-Cell Reports 13, 1481–1492, Nosays with clofazimine and the membrane
targeting antifungal amphotericin B or
the ergosterol biosynthesis inhibitor terbi-
nafine also unveiled enhanced efficacy of
the drug combination in all four species
tested (Figure S5B).
Cells that experience membrane stress
activate the Pkc1 signaling pathway, as
measured by phosphorylation of the
terminal MAP kinase Slt2 (Levin, 2005).
We treated S. cerevisiae with clofazi-
mine and monitored Slt2 phosphoryla-
tion. Exposure to clofazimine increased
phosphorylation of Slt2 relative to total
levels (Figure 6E). The phosphorylationof Slt2 induced by clofazimine occurred regardless of whether
caspofungin, another activator of Pkc1 signaling, was present.
Pkc1 is an essential protein in S. cerevisiae; therefore, we moni-
tored the growth of the PKC1 heterozygous deletion mutant, as
well as growth of homozygous deletion mutants elsewhere in the
pathway in order to determine whether this signaling cascade
was required for tolerance to clofazimine. All mutants displayed
increased sensitivity to clofazimine compared to a wild-type
control strain (p < 0.001, ANOVA, Bonferroni’s multiple compar-
ison test; Figure 6F), except for deletion of SWI4. We also tested
a pkc1D/pkc1D homozygous deletion strain inC. albicans, where
Pkc1 is not essential but is required for tolerance to cell mem-
brane stress (LaFayette et al., 2010). Deletion of PKC1 abolished
growth ofC. albicans in the presence of clofazimine and comple-
mentation of the pkc1 mutation in a pkc1/pkc1 + PKC1 strain
restored growth back to wild-type levels (p < 0.001; Figure 6F).
Taken together, these data suggest that clofazimine elicits a
cell membrane stress response in both C. albicans and
S. cerevisiae, which activates the Pkc1 signaling pathway.
The chemical-genetic profile for clofazimine suggested it
could be generating reactive oxygen species leading to
an oxidative stress against S. cerevisiae. Similar mechanisms
have been reported in Mycobacterium smegmatus such that
growth of the bacteria in the presence of antioxidants blocksvember 17, 2015 ª2015 The Authors 1487
Figure 6. Clofazimine Acts as a Membrane
Perturbing Agent in Fungi
(A) Structures of the membrane perturbing agents
chlorpromazine and clofazimine.
(B) Acidic pH blocks the toxic effects observed by
clofazimine (CLZ). Cells were spotted in 5-fold
dilutions from13 106 cells/ml onto solid buffered
YPD medium with 32 mg/ml of clofazimine as
indicated.
(C) Clofazimine-induced toxicity is rescued by
bafilomycin A. Growth of S. cerevisiae was moni-
tored bymeasuring the OD600 for 36 hr. Area under
the curve (AUC) was calculated and normalized to
solvent treated control. Data are means ± SD of
triplicate experiments.
(D) Elevated temperature exacerbates the synergy
observed between CF and CLZ. Checkerboards
were performed and analyzed as in Figure 4.
(E) Treatment of S. cerevisiae with CLZ activates
Pkc1 signaling as measured by Slt2 phosphoryla-
tion. A strain of S. cerevisiae harboring an allele of
SLT2 C-terminally GFP tagged was treated with
CLZ or CF as indicated. Total protein was resolved
by SDS-PAGE, and blots were hybridized with an
a-phospho p44/42 MAPK antibody to monitor
phosphorylated Slt2 levels and an a-GFP antibody
to monitor total Slt2 levels. ‘‘C’’ indicates untagged
control strain.
(F) Deletion mutants in S. cerevisiae or C. albicans
were grown in the absence and presence of
128 mg/ml CLZ for 26 hr. Area under the curve
(AUC) was calculated in the presence and absence
of drug. Data are means ± SD of quadruplicates.
See also Figure S5.the toxic effects induced by clofazimine (Yano et al., 2011). To
address this possibility, we sought to determine whether we
could abolish the synergy observed between clofazimine and
caspofungin upon addition of antioxidants; however, the synergy
observed between compounds was maintained in the presence
of structurally diverse antioxidants a-tocopherol or N-acetyl-
L-cysteine (Figure S5C). Thus, we propose that the primary
mode of action of clofazimine in yeast is through membrane
perturbation, not through the generation of oxidative stress.
Clofazimine Potentiates Antifungals in Diverse Fungal
Pathogens
To assess the clinical relevance of clofazimine as a combina-
tion agent against fungal pathogens, we assessed its ability to
potentiate caspofungin against diverse Candida species. MIC
assays were performed using a gradient of caspofungin without
and with a fixed dose of clofazimine. The addition of clofazimine1488 Cell Reports 13, 1481–1492, November 17, 2015 ª2015 The Authorsreduced the caspofungin MIC for all
Candida species tested (Figure 7A).
Clofazimine also reduced the caspofun-
gin MIC for three clinical isolates of
C. albicans although to a lesser extent
(Figure 7A). Next, we assessed whether
clofazimine could be used as a combina-
tion agent to treat A. fumigatus infections,
a leading fungal pathogen of humans.Checkerboard assays were performed with a gradient of caspo-
fungin and clofazimine, and growth was monitored by both opti-
cal density and by microscopy due to the filamentous nature of
the fungus. Clofazimine potentiated the activity of caspofungin
against A. fumigatus (Figure 7B), and dramatic reductions in
A. fumigatus hyphal growth and alterations in hyphalmorphology
were observed with the drug combination relative to individual
drug treatments (Figure 7C). Similar effects were seen with the
azole posaconazole in combination with clofazimine (Figure 7C).
Clofazimine thus enhances the efficacy of the azole and echino-
candin antifungal classes in A. fumigatus.
We explored the therapeutic potential of clofazimine in combi-
nation with caspofungin against C. albicans in an in vivo model
of infection. We used a tractable invertebrate model, the greater
wax mothG. mellonella, to study candidiasis in vivo. We injected
each larvae with 105 cells of a clinical isolate of C. albicans
and monitored survival every 24 hr. Injection of larvae with
Figure 7. Clofazimine Potentiates Antifun-
gals in Evolutionary Diverse Fungal Patho-
gens and in an In Vivo Model of Infection
(A) Caspofungin (CF) MIC assays were conducted
against multiple non albicans Candida species and
against clinical isolates of C. albicans that are
known to be resistant to indicated antifungals.
MICs were conducted in the absence (–) or
presence of a fixed concentration of clofazimine
(CLZ). Changes in MIC in the presence of CLZ are
indicated. Data were analyzed as described in
Figure 4.
(B) Checkerboard analysis was conducted with a
gradient of caspofungin and a gradient of CLZ in
A. fumigatus. Growth was quantified and analyzed
as described in Figure 4. See scale bar.
(C) Images show A. fumigatus incubated with CLZ
(16 mg/ml) in combination with posaconazole
(POS, 0.0625 mg/ml) or CF (0.125 mg/ml). Images
were acquired at a 203 magnification. Scale bar,
100 mm.
(D) CLZ potentiates CF in a G. mellonella host-
model system. Sixteen larvae per treatment
group were infected with 105 cells of a clinical
isolate of C. albicans. Larvae were treated with CF
(0.01 mg/kg), CLZ (15 mg/kg), or a combination
once following infection and were scored daily for
viability. p values generated by log-rank (Mantel-
Cox) test. See also Figure S6.C. albicans caused 60% death within 1 day and 100% death
after 4 days (Figure 7D). Treatment of injected larvae with
low doses of individual drug treatments had no effect on sur-
vival. Strikingly, a combination treatment rescued growth of
G. mellonella to a similar level as that observed in the vehicle
control (p < 0.001, log-rank test). Thus, combination therapy
with clofazimine and caspofungin rescues lethal C. albicans in-
fections in an in vivo invertebrate model.
DISCUSSION
There is an urgent unmet clinical need to identify new leads to
treat systemic fungal infections. To address this need, we opti-
mized a systematic approach to uncover compounds previously
unknown to synergize with antifungal agents by combining sub-
lethal concentrations of six known antifungals with 3,600
bioactive compounds, including hundreds of off-patent drugs.Cell Reports 13, 1481–1492, NoBy exploring these interactions in evolu-
tionary diverse fungal species, we un-
veiled a broad spectrum of chemical-
chemical interactions, which we termed
the ACM. This dramatically expands the
spectrum of previously known antifungal
potentiators using molecules that are not
employed as antifungals per se but are
small molecules previously approved for
other indications with well-characterized
pharmacokinetic properties or with other
bioactivities. Within this rich dataset, we
identified a subset of drug combinationsthat were active against a fluconazole-resistant C. albicans clin-
ical isolate, suggesting additional drug combinations in the ACM
are likely active against drug-resistant fungal species. Finally, we
determined the mechanism of action of clofazimine, an antimy-
cobacterial compound for which antifungal activity had not
previously been described, but which we showed has broad
therapeutic potential against fungi. Thus, the ACM dataset is
an invaluable resource for research and clinical communities to
investigate combination therapeutics with favorable efficacy
against harmful fungal pathogens.
Few antifungal potentiators are conserved across the different
fungal species investigated in the ACM. Little cross-species
overlap was also observed in a previous study that specifically
looked for potentiators of fluconazole (Spitzer et al., 2011). The
highly specific effects drug combinations have on distinct spe-
cies can be attributed to multiple factors. Hundreds of millions
of years of evolution have altered the way different speciesvember 17, 2015 ª2015 The Authors 1489
respond to stress induced by small molecules. Fluconazole
alone elicits distinct responses to cope with the drug-induced
stress in different fungal species. S. cerevisiae enhances sterol
import, and C. glabrata enhances fluconazole export to tolerate
azole exposure (Kuo et al., 2010). Further, in S. cerevisiae and
C. albicans distinct cellular circuitries involving the Pkc1 and cal-
cineurin signal transduction cascades are involved in response
to fluconazole (LaFayette et al., 2010). Recently, a large-
scale chemogenomic atlas was generated for C. neoformans
and was compared to similar chemical-genetic profiles in
S. cerevisiae (Brown et al., 2014). The chemical-genetic interac-
tions identified between fungal pathogen and model yeast were
largely distinct, even among orthologous genes (Brown et al.,
2014). Our work further reinforces the importance of pathogen-
focused investigation and is the first dataset of this magnitude
that explores combinatorial agents in two evolutionary diverse
fungal pathogens.
A key public health concern is the rapid development of
resistance many fungal pathogens, most notably C. albicans,
have to current antifungal treatments (Centers for Disease
Control and Prevention, 2013). In a fluconazole-resistant isolate
of C. albicans, we observed potent synergistic interactions
between fluconazole and chlorhexidine, hypocrellin A, or toma-
tidine. There are numerous mutations readily acquired in clin-
ical settings that confer fluconazole resistance in C. albicans
including, but not limited to, mutations in the azole target
Erg11 and mutations involving upregulation of drug efflux
pumps (Shapiro et al., 2011). The nature of the resistance
mechanism often dictates whether particular drug combina-
tions will be efficacious. Mutations in TAC1, a transcriptional
activator of the CDR drug efflux pumps, maintain resistance
to fluconazole in the presence of calcineurin or Hsp90 inhib-
itors (Hill et al., 2015). The clinical isolate used in our studies
harbored several nonsynonymous substitutions in TAC1,
including a hyperactive mutation, Tac1T225A, capable of confer-
ring fluconazole resistance (Coste et al., 2007). We also identi-
fied a nonsynonymous mutation in ERG11 located in a ‘‘hot-
spot’’ region predisposed to mutations that confer fluconazole
resistance (Marichal et al., 1999). Although additional work
remains to assess the impact each of these mutations has in
conferring fluconazole resistance, it remains intriguing that
chlorhexidine, hypocrellin A, and tomatidine are able to poten-
tiate fluconazole in this strain and warrants further investigation
into the manner by which they do so.
We selected clofazimine for mechanistic studies due to its
broad, yet unreported, activity against diverse fungal species.
A genome-wide chemical-genetic profile combined with cell bio-
logical phenotypes suggests clofazimine diffuses across the
plasma membrane and intercalates into the cytosolic side of
the lipid bilayer, which manifests in a cell membrane stress.
This is supported by studies in bacteria that have shown clofazi-
mine is a membrane-destabilizing agent, dismantling membrane
architecture directly and by interacting with lysophospholipids
(Cholo et al., 2012). Recently, derivatives of amphotericin B
were generated that displayed high selectivity to pathogen-
specific lipids in vitro and potent efficacy in mouse models of
fungal pathogenesis (Davis et al., 2015). These compounds
strongly evaded the emergence of resistance, likely because1490 Cell Reports 13, 1481–1492, November 17, 2015 ª2015 The Auergosterol serves as a central molecular node in a myriad of
essential cellular processes (Davis et al., 2015). As our work im-
plicates membrane lipids as a target of clofazimine, we postulate
this compound could similarly impede resistance development.
Clofazimine dramatically improved the efficacy of caspofungin
in non-albicans Candida. Notably, the incidence of candidemia
due to other Candida species such as C. parapsilosis and
C. glabrata has increased significantly over the last 2 decades
(Cleveland et al., 2012). Alarmingly, resistance to fluconazole
and echinocandins is more common in non-albicans Candida
compared with C. albicans isolates (Cleveland et al., 2012),
necessitating the development of new treatment strategies in
these species. As predicted by our in vitro data, combination
therapy with clofazimine and caspofungin rescues a lethal
C. albicans infection in the invertebrate host G. mellonella. How-
ever, preliminary experiments in a mouse model of disseminated
C. albicans infection did not support our in vitro data (Figure S6),
presumably due to unfavorable pharmacokinetic properties
against the drug combinations in this more complex model sys-
tem. Additional experiments using altered routes of administra-
tion and/or infections with other fungal pathogensmay still unveil
conditions for the use of clofazimine as a treatment for fungal
infections.
The generation of the ACM charted a new realm of chemical
space, which has been and will continue to be exploited for
both fundamental biological research and as an approach to
accelerate drug development. We know more efficacious and
specific intervention for the treatment of infectious disease can
be achieved through the combinations of bioactive compounds.
The challenge that remains for us and other members of the
medical mycology community is to identify and explore those
combinations whose strong in vitro synergistic interactions can
be translated to potent therapies in mammalian models of fungal
infections.
EXPERIMENTAL PROCEDURES
Ethics Statement
Animals studies were conducted in the Division of Laboratory Animal Re-
sources (DLAR) facilities at Duke University Medical Center (DUMC) in good
practice as defined by the United States Animal Welfare Act and in full compli-
ance with the guidelines of the DUMC Institutional Animal Care and Use Com-
mittee (IACUC). The vertebrate animal experiments were reviewed and
approved by the DUMC IACUC under protocol number A114-14-05.
Strains and Culture Conditions
Strains are listed in Table S7, and culture conditions are described in the
Supplemental Experimental Procedures.
High-Throughput Screening
The McMaster Bioactives collection was screened at a final concentration of
12.5 mM in the presence and absence of 1/4MIC antifungal. Screens were per-
formed using C. albicans (ATCC 90028), C. neoformans (H99), S. cerevisiae
(BY4741), and S. pombe (ATCC 38366). Details of screening methods are
described in the Supplemental Experimental Procedures. In brief, screens
were conducted in duplicate in 384-well flat-bottom microtiter plates (Thermo
Scientific) at a final volume of 80 ml. For preparation of diluted yeast culture,
liquid overnight cultures were diluted to an OD600 of 0.14, followed by a
1:1,000 dilution in synthetic complete (SC) media. Plates were incubated at
30C and OD600 was measured after 48 hr of growth for S. cerevisiae and
C. albicans or 72 hr of growth for C. neoformans and S. pombe. All data werethors
normalized for plate- and row/column-specific effects as described previously
(Spitzer et al., 2011). Screen hits were those compounds that were threeMADs
below thediagonal, inhibitedgrowthon their own less than50%,and resulted in
at least 80% growth inhibition in the presence of the antifungal. Chemical-
chemical interactions were generated using the program Cytoscape v3.2.1
using a spring embedded algorithm (http://www.cytoscape.org).
Drug Susceptibility Assays
All compounds were purchased from Sigma Aldrich with the exception of cas-
pofungin (Cancidas) and posaconazole, which were purchased from Merck,
and hypocrellin A, which was purchased from Abcam. DMSO (Sigma-Aldrich)
was the solvent for all compounds. Drug susceptibility assays were performed
as described previously (LaFayette et al., 2010). Details of protocol are
described in the Supplemental Experimental Procedures. For A. fumigatus,
drug susceptibility was determined using a 24-well plate assay (Corning).
Each well was inoculated with 105 conidia of A. fumigatus Af293. The plates
were incubated at 37C and 5% CO2 and examined after 24 and 48 hr under
an inverted light microscope (Zeiss). Images acquired using Infinity2 camera
(Lumenera).
Cidality Assays
Viability of cultures after treatment with a gradient of fluconazole in combina-
tion with a gradient of ACM compound were tested by spotting 2 ml on YPD
plates after yeast cells had been incubated with compound for 48 hr. YPD
agar plates were incubated at 30C for 48 hr prior to imaging.
Spotting Assays
Strains were grown to saturation in YPD, and cell concentrations were stan-
dardized based on optical density. 5-fold dilutions (from z1 3 106 cells/ml)
were spotted onto pH-buffered media with and without clofazimine. Plates
were photographed after 2 days in the dark at 30C.
Chemical-Genomic Assays
S. cerevisiae deletion collections (MATa haploid and heterozygous essential
deletion strains) were obtained from Research Genetics (Germany). Details
of protocol are described in the Supplemental Experimental Procedures. In
brief, compounds were screened at a concentration that inhibited growth of
the pool by 20% relative to a solvent control. Deletion pools were grown
for 24 hr at which point gDNA was extracted using phenol-chloroform extrac-
tion methods. Purified gDNA was used to amplify the barcoded tags up-
stream of the KANMX cassette using various primer combinations (Table
S8). PCR products were pooled and sequenced at the Farncombe Metage-
nomics Facility at McMaster University. p values for Gene Ontology (GO)
enrichment were calculated through the Gene Ontology Consortium resource
(http://geneontology.org) (Gene Ontology, 2015).
Immune Blot Analysis
Immunoblotting was conducted as described previously (LaFayette et al.,
2010). In brief, a strain of S. cerevisiae harboring a GFP epitope tag on Slt2
was grown overnight in YPD at 30C without and with 10 mg/ml of clofazimine.
In the morning, cells were diluted to OD600 of 0.2 in 125 ml of YPD without or
with clofazimine and grown to mid-log (5 hr) at 30C. Cultures were split and
left untreated or treated with 50 ng/ml of caspofungin for 30 min. Cells were
harvested and total protein extracts were prepared as described previously
(Robbins et al., 2011). Protein concentrations were determined by Bradford
analysis. Samples were separated by 10% SDS-PAGE. Protein was electro-
transferred to polyvinylidene fluoride (PVDF) membrane, blocked with 5%
BSA in Tris-buffered saline with 0.1% Tween. Blots were hybridized with anti-
bodies against GFP (1:750 dilution, Cell Signaling Technology, 2956P) and
phospho-p44/42 MAPK (Thr202/Tyr204) (1:750, Cell Signaling Technology,
9101S).
G. mellonella Antifungal Assay
Injection of C. albicans and antifungal drugs was performed essentially as
described (Fuchs et al., 2010). In brief, larvae in the final instar were obtained
from Reptilia: Reptile Zoo and Educational Facility. Sixteen larvae (275 ±
25 mg) were used per group. Each injection of 5 ml of fungus, drug, or controlCell Repinto the hemocoel was performed via a distinct proleg. Drugs were injected af-
ter inoculum delivery. Larvae were incubated at 37C, and the number of dead
larvae was scored daily. C. albicans inoculum was prepared by growing YPD
cultures overnight at 30C. Cells were washed three times in PBS, densities
were determined by hemacytometer count, and dilutions were prepared in
PBS. Kill curves were plotted and estimation of differences in survival (log-
rank test) analyzed by the Kaplan-Meier method (GraphPad Prism). Killing
assays were performed twice using distinct batches of G. mellonella.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.10.018.
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